Market Newsdesk

Investigational drug
RNL
™
d
eliver
s
u
p to
fifteen
t
imes
the
a
bsorbed
d
ose of
r
adiation
c
ompared to
standard
e
xternal
b
eam
r
adiation
t
herapy

RNL was
g
enerally
well-
t
olerated
w
ith
n
o
d
ose-
l
imiting
t
oxicities
o
bserved

Company
m
anagement and
p
rincipal
i
nvestigator
of ReSPECT
to
d
iscuss
i
nterim
d
ata
d
uring
w
ebinar
s
cheduled for
Thursday
,
November
19
, 20
20
at
4
:30
–
5:30 p.m.
ET

AUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced positive new interim data from its ongoing ReSPECT™ Phase 1 clinical trial evaluating the Company’s lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM). These results were presented in an electronic poster entitled, “Safety and Feasibility of Rhenium-186 Nanoliposomes (RNL™) in Recurrent GBM: the ReSPECT Phase 1 Trial,” at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting, which is taking place virtually November 19-21, 2020.

The interim data set shows that intratumoral RNL can successfully deliver up to fifteen times the absorbed dose of radiation administered by standard external beam radiation therapy (EBRT) without significant toxicity. These data support progression to the ReSPECT trial’s sixth dose escalation cohort.

“The results we have seen thus far from ReSPECT are encouraging and support the continued development of RNL as a potential new option for recurrent GBM patients,” said Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas, Health Services Center at San Antonio and principle investigator of the study. “With limited therapeutic options for these patients, we remain committed to advancing this clinical program to further investigate the therapeutic potential of RNL.”

“Treatment for glioblastoma remains a significant challenge as current therapies have exhibited limited efficacy,” stated Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. “RNL’s novel design allows the drug to be targeted directly into the tumor using a small catheter and enabling greater control of radiation dosing. These encouraging data reinforce RNL’s potential to deliver targeted high-dose radiation in a safe, effective, and convenient manner.”

Key
R
esults from the
I
nterim
A
nalysis

• All 15 patients in the first five of six planned cohorts have completed treatment.
• RNL treatment volume and radiation dose increased successfully from 0.66 milliliter (mL) to 8.8 mL and 1.0 millicurie (mCi) to 22.3 mCi, respectively.
• Cohort 5 patients received an RNL average absorbed radiation dose of 423 Gray (Gy).
• RNL has been well-tolerated, and no dose-limiting toxicity has been observed despite markedly higher absorbed doses of radiation compared to EBRT.
• Most adverse events (AEs) were considered causally unrelated to RNL except scalp discomfort, which was considered related to the surgical procedure. Neither the incidence nor severity of AEs appeared to increase with increasing doses of RNL.
• Four serious adverse events (SAEs) were reported, none of the SAEs were considered causally related to RNL.
• Median survival duration in patients that previously received bevacizumab (n=7) was 4.8 months, while median and mean survival durations in patients that were bevacizumab-naïve (n=8) are currently 11.0 months (range 3.5 – 33) and 15.4 months (95% CI 7.4 – 23.4), respectively, with four patients still alive.
• Two patients survived greater than 30 months after therapy with RNL.

The sixth dose escalation cohort of the ReSPECT trial is underway and one patient has thus far been treated. The sixth cohort is expected to fully enroll by the end of 2020. In September 2020, the U.S. Food and Drug Administration (FDA) granted both Orphan Drug designation and Fast Track designation to RNL for the treatment of patients with glioblastoma. Additional details about the ReSPECT trial are available at clinicaltrials.gov (NCT01906385).

Webinar details

The Company will host a webinar today, Thursday, November 19, 2020, 4:30 to 5:30 p.m. ET discussing these data. Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas, Health Services Center at San Antonio, will provide an update on the ReSPECT trial and provide insight on the trial data. In addition, a patient with recurrent GBM from the ReSPECT trial will provide their treatment experience with RNL.

Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, and Gregory D. Stein, M.D., M.B.A., Senior Vice President, Clinical Development of Plus Therapeutics, will discuss the technology behind RNL as well as the current treatment landscape and unmet medical need in treating patients with recurrent GBM.

The live webinar with accompanying slides will be available in the Events page of the ‘Investors’ section of the Plus Therapeutics website or by clicking here. Individuals can participate in an interactive Q&A session by submitting pertinent questions via the webcast platform.

Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events section of the Company’s website for 90 days.

A live audio conference will be available by dialing (833) 340-0285 (toll-free) or (236) 712-2475 and entering Conference ID 6095968.

Andrew J. Brenner, M.D., Ph.D.

Dr. Brenner is a nationally known expert in the treatment of brain and breast cancers, with a particular research interest in developing new treatments. He has served on multiple committees and panels including for the National Institutes of Health, National Cancer Institute, Department of Defense Breast Cancer Research Program, and others. He has also served on advisory committees for a number of companies to help direct development of new drugs. His laboratory work developing new treatments has been funded by the Food and Drug Administration, National Cancer Institute, and Cancer Prevention and Research Institute of Texas. He has published nearly 50 original research articles in peer reviewed journals. Dr. Brenner is a member of the Plus Therapeutics Scientific Advisory Board.

About Plus Therapeutics, Inc.

Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company’s potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company’s potential to develop drug candidates currently in its product pipeline; and the Company’s potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA’s accelerated regulatory pathways; and the risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
[email protected]

Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
[email protected]

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5639e2df-2399-4963-8796-f86e100ffa8e

 

VANCOUVER, British Columbia, Nov. 19, 2020 (GLOBE NEWSWIRE) — Evolving Gold Corp. (CSE: EVG) (FSE: EV71) (OTCB: EVOGF) (the “Company” or “EVG”) announces that due to the sudden passing of Mr. R. Bruce Duncan, our Chief Executive Officer, last week certain interim appointments have been made.

The board has appointed Mr. Charles Jenkins CPA, CGA, the company’s chief financial officer for the past ten years as interim chief executive officer, effective immediately. Mr. Jenkins has also been appointed as a director of the Company.

The board is reviewing the Company overall, and is actively reviewing opportunities to advance the Company. Further announcements will be made as and when appropriate.

On Behalf of the Board of Directors

EVOLVING GOLD CORP.

“Robert Horsley”

Director
[email protected]

Neither Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

REDWOOD CITY, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq:RZLT), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced today that Nevan Charles Elam, the Company’s CEO and founder, will be presenting a corporate overview as part of the upcoming Piper Sandler 32^nd Annual Virtual Healthcare Conference. Beginning November 23, the presentation will be available for viewing anytime through December 3 by accessing the recording library on the Piper Sandler conference site.

Rezolute will also be participating in 1×1 meetings which can be requested via Piper Sandler.

About Rezolute, Inc.

Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for congenital HI, a rare pediatric endocrine disorder. Its pipeline also includes RZ402, an IND-ready orally available plasma kallikrein inhibitor which is staged to transition into clinical development for the treatment of diabetic macular edema. For more information, visit www.rezolutebio.com or follow us on Twitter.

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute, Inc. and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

Media Contact

Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
[email protected]

Investor Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]

DENVER, Nov. 19, 2020 (GLOBE NEWSWIRE) — NewAge, Inc. (Nasdaq: NBEV), the Colorado-based social selling and distribution company with a network of independent business owners across 75 countries worldwide, today announced that it has appointed Dr. Fred W. Cooper, Ph.D., as a member of its board of directors, effective November 16, 2020.

Dr. Cooper brings more than 25 years of e-commerce and direct selling experience and was a Founder and the Chief Executive Officer of ARIIX prior to completing the merger. Under Dr. Cooper’s leadership, ARIIX was one of the fastest-growing direct selling companies over its nine years of business, and in 2020, was recognized as number 35 on the DSN’s list of Top 100 global companies. Prior to founding ARIIX in July 2011, he was the President and Chief Operating Officer of NYSE listed USANA Health Sciences. He started his career in direct sales at USANA in 1998 where he played many critical roles, serving in different executive capacities in Special Projects, Information Technology, and Global Operations. Dr. Cooper also spent over ten years teaching entrepreneurship and statistics courses as a part-time professor at the University of Utah.

Dr. Cooper earned a B.S. in Finance and a B.S. in Psychology from the University of Utah. He also earned a Ph.D. in Business Administration, with an emphasis on statistics and operations processes and management, from the University of Utah

Greg Fea, Chairman of the Board of NewAge, commented, “We are pleased to welcome Dr. Cooper to the Board and look forward to working closely with him to further the success of NewAge. His expertise in Direct Sales at the highest levels makes for a natural addition as we continue to execute our direct-to-consumer strategy. His track record in the industry is unmatched, which along with his diverse experience as a successful business owner, entrepreneur, and a former top executive of a publicly-traded company, significantly strengthens the NewAge Board.”

In response to his appointment to the Board of Directors of NewAge, Dr. Cooper commented, “I’m excited to take on a new responsibility to help guide the strategic direction of NewAge, combining our global leading companies. I know and have worked personally with many of the new executives of NewAge and have a high level of confidence in their leadership and abilities. NewAge is well-positioned globally to drive growth, improve profitability, and reach more consumers than ever before. I look forward to playing a significant role to help further the company’s position in the global consumer market to create additional value for all of our representatives, consumers and shareholders.”

About


NewAge


, Inc.


(NASDAQ:


NBEV


)


NewAge is a Colorado-based organic and healthy products company dedicated to inspiring and educating consumers to “Live Healthy.” The Company is a social selling and distribution company with access to e-commerce, direct-to-consumer, and medical channels across more than 75 countries worldwide when combined with ARIIX. NewAge markets a portfolio of better-for-you products including the brands Tahitian Noni, TeMana, ‘Nhanced and others. The Company operates the websites www.newage.com, www.noninewage.com, and a number of other individual brand websites.

Safe Harbor Disclosure


This press release contains forward-looking statements that are made under the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statement reflecting management’s expectations regarding future results of operations, economic performance, financial condition, the acquisition of ARIIX, statements about the benefit of the ARIIX transaction, and the extent and duration of COVID-19 on its business. The forward-looking statements are based on the assumption that operating performance and results will continue in line with historical results. Management believes these assumptions to be reasonable, but there is no assurance they will prove to be accurate. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially. NewAge competes in a rapidly growing and transforming industry, and risk factors, including those disclosed in the Company’s filings with the Securities and Exchange Commission, might affect the Company’s operations. Unless required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements.

For investor inquiries about NewAge please contact:

NewAge
Investor Relations:

Riley Timmer
Vice President, Investor Relations
Tel: 1-801-870-8685
[email protected]

Investor Relations Counsel:

John Mills/Scott Van Winkle
ICR – Strategic Communications and Advisory
Tel: 1-646-277-1254/1-617-956-6736
[email protected]

NewAge
, Inc.
:

Gregory A. Gould
Chief Financial Officer
Tel: 1-303-566-3030
[email protected]

BARTLETT, Tenn., Nov. 19, 2020 (GLOBE NEWSWIRE) — SurgePays, Inc. (OTCQB: SURG) (“SurgePays” or the “Company”), a fintech company meeting the needs of the underserved and underbanked, announces today that the Company has been named to the Deloitte Technology Fast 500 2020 North America for the second year running.

“Inclusion into the Deloitte Technology Fast 500 is a milestone event for the company as it provides outside validation for our SurgePays fintech platform, which is designed to more efficiently provide products and services to the underbanked population via the retail locations that serve them,” said SurgePays CEO and Chairman Brian Cox. “We are gratified to have been included for two years, which we believe validates our business approach and reinforces our dedication toward growth. However, we continue to evolve the company even now, identifying the best opportunities to maximize value while serving our customers and look forward to continuing to rise in the rankings as our growth reflects our success.”

Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, and energy tech companies—both public and private—in North America. The 2020 Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth during the period from 2016 to 2020.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or proprietary technology and it must be sold to customers in products or services that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $50,000 USD, and current-year operating revenues of at least $5 million USD. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

The rankings are compiled from applications submitted directly to the Technology Fast 500 website, and public company database research conducted by Deloitte LLP.

About
SurgePays
, Inc.
SurgePays, Inc. is meeting the needs of underserved markets in financial technology, telecommunications, and digital media. It offers prepaid wireless and underbanked financial products and services, along with popular consumer goods, to retail merchants (such as operators of convenience stores, bodegas, and gas stations) that address the needs of many store customers nationwide. Please visit www.SurgePays.com for more information.

Company Contact:

Tony Evers CPA, CIA
Chief Financial Officer
Chief Operating Officer
Cell: (262) 347-7289
[email protected] 

Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
[email protected] 

Investor Relations Contact:
CORE IR
Joseph Delahoussaye III
V.P. of Investor Relations
516-222-2560
[email protected] 

QUICK TAKE:

• The most standard safety features in its class¹, including standard Nissan Safety Shield^® 360
• Comprehensive suite of intelligent connectivity technologies, including standard Apple CarPlay^® integration and Android Auto™, available NissanConnect^® Services and NissanConnect with Wi-Fi hotspot
• Responsive 149-horsepower, 2.0L 4-cylinder engine with 146 lb-ft of torque
• Advanced driving dynamics with independent rear suspension and dual pinion electric steering
• Multiple awards won in debut 2020 model year, including top segment honors in the J.D. Power 2020 Automotive Performance, Execution and Layout (APEAL) Study^SM

NASHVILLE, Tenn., Nov. 19, 2020 (GLOBE NEWSWIRE) — The surprising Nissan Sentra, which was completely redesigned inside and out just one year ago, represented a breakthrough for Nissan’s popular compact sedan – winning numerous prestigious industry awards along the way. Nissan today announced a starting MSRP² of $19,410 U.S. for the 2021 model, which is on sale now at Nissan dealers nationwide.

Changes for 2021 include the addition of Apple CarPlay^® integration and Android Auto™ as standard equipment on all trims (previously available on SV and SR grades), available NissanConnect^® Services and NissanConnect with Wi-Fi hotspot on SR grade and a new two-tone paint combination – Electric Blue Metallic with Black roof for the SR grade.

Manufacturer’s Suggested Retail Prices² for the 2021 Nissan Sentra:

Sentra S	$19,410 USD
Sentra SV	$20,470 USD
Sentra SR	$21,750 USD

Destination and Handling $925.

About the 2021 Nissan Sentra


Now in its eighth generation, Sentra has been transformed from a traditional compact sedan to a powerful presence that shares the muscular, sporty design elements from models like Maxima and Altima. It also features a refined, premium interior that sets the standard for quality and comfort in its class.

In its debut year, the new-generation won numerous prestigious industry awards, including:

• J.D. Power 2020 Automotive Performance, Execution and Layout (APEAL) Study^SM, scoring 42 points above segment average
• Autotrader’s “Best New Cars of 2020” and “10 Best Cars for Recent College graduates”
• WardsAuto’s 10 Best Interiors for 2020WardsAuto

Sentra’s driving experience continues to stand out in 2021. Sentra’s fuel-efficient 2.0-liter DOHC 4-cylinder engine delivers 149 horsepower and 146 ft-lb of torque – increases of 20 percent and 17 percent respectively over the previous generation. Sentra’s top-level driving dynamics are provided by an independent rear suspension matched to a MacPherson strut front suspension with twin-tube shock absorbers. A responsive dual pinion rack electric power steering system and Nissan Intelligent Trace Control technology are both standard.

Nissan Safety Shield^® 360 is standard on all 2021 Sentra grade levels and includes Automatic Emergency Braking with Pedestrian Detection, Blind Spot Warning, Rear Cross Traffic Alert, Lane Departure Warning, High Beam Assist and Rear Automatic Braking. Sentra also features standard Rear Door Alert, 10 supplemental air bags and Intelligent Driver Alertness³.

For more information on the 2021 Sentra, along with the complete lineup of Nissan vehicles, please visit NissanNews.com.

For more information about our products, services and commitment to sustainable mobility, visit nissanusa.com. You can also follow us on Facebook, Instagram, Twitter and LinkedIn and see all our latest videos on YouTube. Media Contact: Jonathan Buhler Product Communications – Sports Cars and Sedans Phone 615/725-0966 [email protected]

1. Ward’s Upper-Small Segmentation. 2021 Sentra vs. latest in-market competitors. See Owner’s Manual for safety information. Availability of features vary by vehicle model year, model, trim level, packaging and options. Base models compared. Based on manufacturers’ websites.
2. MSRP excludes applicable tax, title, license fees and destination charges. Dealer sets actual price. Prices and specs are subject to change without notice. Destination and handling $925.
3. It is the driver’s responsibility to remain alert at all times. Intelligent Driver Alertness is only a warning to inform the driver of a potential lack of driver attention or drowsiness. It does not detect and provide an alert in every situation. See Owner’s Manual for details.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5b9b81b7-d049-467b-8837-8c4cf55fef88

LARGO, FL, Nov. 19, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Today, Leone Asset Management (OTC PINK: LEON) Subsidiary JP Anderson, Ltd. announced that they have entered into a Memorandum of Understanding (MOU) with Ken Davidson Agricultural Development and Construction Company, Ltd., in Sierra Leone, West Africa.

The MOU agreement between the two parties is to undertake the business of quarrying, leading to the crushing of stone for infrastructure development in Sierra Leone and other countries in West Africa.  JP Anderson will be operating a 65-acre quarry location near the Capitol City of Freetown in Sierra Leone.  The quarry location has well in excess of one billion US dollars in crushable stone and the agreement is in place for 25 years. The parties anticipate to begin operation in the first quarter of 2021.

James Price, Chairman and CEO of Leone Asset, stated, “This is an extraordinary opportunity for Leone Asset.  The country of Sierra Leone is going through tremendous infrastructure development with constant growth of road and bridge construction as well as a new airport and a six mile long bridge from the Lungi airport into Freetown. 

We anticipate to begin operations with a 350 ton per hour crushing plant and operating six days per week with two eight hour shifts daily.

This opportunity and corporate expansion will add tremendous share-holder value and will allow Leone Asset to participate with Sierra Leone and other sub-sahara countries with some of the World’s largest infrastructure development over the next fifty years.” 

About Leone Asset Management 

Leone Asset Management, Inc., is a multi-national, multi-industry conglomerate with subsidiary companies that operate in Health and Wellness, Media & Communications, Infrastructure development, agriculture management and mining exploration. For additional information, please visit www.leoneasset.com. 

Forward-Looking Statements Disclosure:

This press release may contain “forward-looking statements” within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company’s expected future business and financial performance, and often contain words such as “anticipates,” “beliefs,” “estimates,” “expects,” “intends,” ” plans,” “seeks,” “will,” and other terms with similar meaning. These forward-looking statements by their nature address matter that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.

Contact:

James Price

[email protected]

727-581-1500

HOLLYWOOD, Fla., Nov. 19, 2020 (GLOBE NEWSWIRE) — NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of compliance, technology, and engineering consulting solutions, announced today that it has been selected to provide $8 million in engineering, procurement, and construction (EPC) services to upgrade a liquefied natural gas (LNG) facility owned and operated by a Northeast utility. The improvements are part of a multi-phase project, and NV5 was previously awarded the engineering and design for the upgrade. The updated facility will increase the safety, efficiency, and reliability of the gas supply to the utility’s service area.

“We have seen significant growth in this sector as we support utility investments to modernize the electrical grid and gas distribution infrastructure and improve the reliability and safety of transmission and distribution,” said Dickerson Wright, PE, Chairman and CEO of NV5. “NV5’s expertise in engineering design, inspection, quality assurance, and geospatial solutions for the utility industry provides a turnkey solution for our clients and a competitive advantage for our Utility Services vertical.”

“We are pleased to contribute to the reliable delivery of natural gas to our utility clients’ service areas through improvements to the safety and efficiency of their liquefaction and other plant systems,” said Peter Dirksen, PE, President of NV5 LNG Services.

About NV5

NV5 Global, Inc. (NASDAQ: NVEE) is a leading provider of compliance, technology, and engineering consulting solutions for public and private sector clients supporting infrastructure, utility, and building assets and systems. The Company primarily focuses on six business verticals: testing, inspection & consulting, infrastructure support services, utility services, buildings & program management, environmental health sciences, and geospatial technology services. NV5 operates out of more than 100 offices nationwide and abroad. For additional information, please visit the Company’s website at www.NV5.com. Also visit the Company on Twitter, LinkedIn, Facebook, and Vimeo.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The Company cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained in this news release. Such factors include: (a) changes in demand from the local and state government and private clients that we serve; (b) general economic conditions, nationally and globally, and their effect on the market for our services; (c) competitive pressures and trends in our industry and our ability to successfully compete with our competitors; (d) changes in laws, regulations, or policies; and (e) the “Risk Factors” set forth in the Company’s most recent SEC filings. All forward-looking statements are based on information available to the Company on the date hereof, and the Company assumes no obligation to update such statements, except as required by law.

Investor Relations Contact

NV5 Global, Inc.
Jack Cochran
Vice President, Marketing & Investor Relations
Tel: +1-954-637-8048
Email: [email protected]

Source: NV5 Global, Inc.

NEWARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) — Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today announced the presentation of interim clinical data from its Phase 1 trial evaluating TNB-383B in relapsed/refractory multiple myeloma (R/R MM) at the 62^nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually Dec. 5-8, 2020. TNB-383B is a fully human bispecific antibody that targets BCMA on the surface of multiple myeloma (MM) cells and CD3 on the surface of T cells in order to trigger lysis of MM cells in R/R MM patients. The open-label multi-center trial is designed to assess the safety, pharmacokinetics and preliminary efficacy of TNB-383B administered intravenously once every 21 days.

The interim results will be presented on Saturday Dec. 5 at 2:45 pm PT in an oral presentation by Cesar Rodriguez, M.D. (Wake Forest Baptist Health) titled “Interim Results of a Phase I Study of TNB-383B, a BCMAxCD3 T-cell Redirecting Antibody in Relapsed/Refractory Multiple Myeloma”. The presentation will summarize interim data from 58 patients receiving escalating doses from 0.025 mg – 60 mg. Since the study is still ongoing, 81% of responders continue on treatment. Early results show an improved safety and efficacy profile.

“We are very pleased with the clinical data described in this presentation. It is encouraging to see the clinical benefit driven by T-cell mediated tumor lysis without the accompanying safety signals related to cytokine release that are typically associated with immune-activating therapies. The dosing schedule of once every three weeks allows for reduced clinic visits compared to other BCMAxCD3 bispecifics in development. Overall, we are excited to see the unique attributes of Teneobio’s CD3-engager platform validated in the clinic. We look forward to continued development of TNB-383B as well other bi-specific antibodies in our pipeline,” said Ben Buelow, M.D., Ph.D., Chief Medical Officer of Teneobio.

About Teneobio, Inc.

Teneobio, Inc. is a clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb^®), for the treatments of cancer, autoimmunity, and infectious diseases. Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat^® and OmniFlic^®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest. Versatile antibody variable domains (UniDab^®) derived from UniAb^® can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics. Teneobio’s “plug-and-play” T-cell engaging platform includes a diverse set of anti-CD3 antibodies for therapeutics with optimal efficacy and reduced toxicity.

Teneobio partners include AbbVie, Janssen, GSK, Kite, Poseida, Intellia, and ArsenalBio. For more information, please visit www.teneobio.com.

Company Inquiries for Teneobio, Inc.

Omid Vafa, Chief Business Officer
[email protected]

 

Corporate status and plans fiscal 2020 and 2021

Las Vegas, NV, Nov. 19, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — GZ6G Technologies Corp. (OTCMarkets: GZIC) was established to acquire emerging 5G smart technology enabled companies with a demonstrated niche product offerings, established customers and leadership to drive scalable recurring revenue for growth.

“The Covid 19 pandemic has created an unavoidable operational delay and financial impact on a global scale for most businesses.  Operating businesses and industry partners in our market space across the globe, have shifted their sales teams and core management to home offices in order to allow continued operations through this difficult time.  This shift in operational format has allowed the Company to pause, pivot, and adjust to the circumstances so that we will be ready for a return to full scale operations in 2021.”  

Mr. Smith further stated, “The impact Covid-19 has had on travel, cities, stadiums and universities’ hospitality worldwide has been much greater than initially anticipated.  During this time, GZIC has managed to continue working with accountants, attorneys and our telecom strategic partners and clients to adjust to these new circumstances. We have planned and are preparing our rollout strategies for 2021 and beyond.  In my opinion, there will be new opportunities and challenges ahead, and we will continue to pivot to meet market demand which means staying healthy, positive and focused on our future.  Let’s hope and pray for a healthy and speedy recovery to us all as we move forward into 2021,” concluded Coleman Smith, CEO GZ6G Technologies Corp.

Shareholder update:

Corporate Mission

Our corporate mission remains unchanged: to become one of the nation’s leading providers of in venue security and marketing solutions powered by content and technology.  The Company has developed and focused on specialization in the emerging 5G wireless, deep data analytics platforms and Artificial Intelligent machine learning solutions market that targets all types — stadiums, airports, universities, cities and hospitality industries.

Our plans have been expanded to include acquisitions of complementary businesses that can allow us to achieve increased revenue goals on a  shorter timeline, given the ongoing impact of the Covid-19 pandemic.

UP-Listing Update OTC:QB

The impact globally of the Covid-19 pandemic has pushed our initial up-list plans forward into 2021 due to uncertainty in global markets over the last several months.  We are positioning the Company to capitalize on our immediate market opportunities, starting in 2021 and are hopeful to secure our listing on OTC:QB in the first quarter of 2021.

Green Zebra Media Corp.

Our operating subsidiary, Green Zebra Media Corp., a provider of wireless hardware gateways, communications, marketing and sponsorship, Data Analytics platform and CRM technology for stadiums, cities, airports and universities and hospitality markets, is focused on a return to our previously scheduled operations, prior to the onset of the Covid-19 pandemic.  We expect to return staff from furlough and/or retain additional employees during the fourth quarter of fiscal 2020 to continue to work to fulfilling the terms of existing service contracts with various venues and facilities.  The focus of Green Zebra will be those contracts which can most efficiently, and cost effectively bring additional revenue generating operations on board as venues and industries must adapt to the new 5-G environment.

Preparing for Emerging Market

Coleman Smith / CEO of GZ6G Technologies Corp stated, “By 2035, ABI Research (5G urban deployment: debunking the capex myth and unlocking new growth) predicts that the 5G market will generate 17 trillion in total economic value; even the government calls for nationalizing the USA market. 5G wireless and IOT software technology solutions will be the greatest opportunity since the birth of the internet.  In my opinion, the 5G market is emerging and creating new industries and opportunities that require cities and venues to update their wireless infrastructure security, user engagement technologies and machine learning data analytics. The Covid-19 pandemic is expediting business awareness for various types of wireless and mobile IoT technologies.”

Mr. Smith further added, “It’s an excellent opportunity to enter the emerging early stage 5G market by acquiring small to medium wireless infrastructure and smart software technology companies to grow revenues while creating a family of companies that work together to meet demands for the 5G technology rollout.”

About GZ6G Technologies Corp.

GZ6G Technologies Corp. (OTC: GZIC), a wireless Internet of Things  (IoT) technology holdings company, is focused on acquiring, developing and overseeing innovative wireless IoT technology companies for the emerging 5G marketplace, including  target markets such as Stadiums, Airports, Universities, and Smart City Projects.

Safe Harbor Statement

Safe Harbor Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company denies any responsibility to update any forward-looking statements.

To be added to our distribution list, please email, [email protected]   
For more information, visit us at www.GZ6G.com, www.twitter.com/GZ6tech
Contact Information [email protected]  

SOURCE:  GZ6G Technology Corp. (formerly Green Zebra International Corp.)